1501180-15-9

Basic information

• Product Name: 2-(2,6-difluoro-4-methoxyphenyl)thiazole-4-carboxylic acid
• Synonyms: 2-(2,6-difluoro-4-methoxyphenyl)thiazole-4-carboxylic acid
• CAS NO: 1501180-15-9
• Molecular Weight: 271.244
• Mol File: 1501180-15-9.mol

Chemical Properties

• CAS DataBase Reference: 2-(2,6-difluoro-4-methoxyphenyl)thiazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,6-difluoro-4-methoxyphenyl)thiazole-4-carboxylic acid(1501180-15-9)
• EPA Substance Registry System: 2-(2,6-difluoro-4-methoxyphenyl)thiazole-4-carboxylic acid(1501180-15-9)

Safety Data

• Hazardous Substances Data: 1501180-15-9(Hazardous Substances Data)

Upstream product

• 406482-20-0 (2,6-difluoro-4-methoxyphenyl)boronic acid 
• 13716-12-6 tri-tert-butyl phosphine 
• 1586045-15-9 methyl 2-(2,6-difluoro-4-methoxy-phenyl)thiazole-4-carboxylate 
• 170235-26-4 2-bromo-thiazole-4-carboxylic acid methyl ester 

Downstream Products

• 1586041-34-0 N-(5-((2S,5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluoro-4-methoxyphenyl)thiazole-4-carboxamide 
• 1586041-26-0 N-(5-((2S,5R,6R)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluoro-4-methoxyphenyl)thiazole-4-carboxamide 

Relevant articles and documents

OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Oxepan-2-yl pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for in

CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.